Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (vol 389, pg 67, 2017)

被引：0
|
作者：
Balar, A., V
Galsky, M. D.
Rosenberg, J. E.
机构：
来源：
LANCET | 2017年 / 390卷 / 10097期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：848 / 848
页数：1
相关论文
共 50 条
  • [1] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    LANCET, 2017, 389 (10064): : 67 - 76
  • [2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2017, 18 (11): : 1483 - 1492
  • [3] BUDGET IMPACT ANALYSIS OF PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN AS FIRST-LINE TREATMENT OF CISPLATIN-INELIGIBLE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN USA
    Lai, Y.
    Guo, H.
    Arku, D.
    Meng, Y.
    Li, H.
    VALUE IN HEALTH, 2023, 26 (06) : S88 - S88
  • [4] Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean
    Powles, Tom
    van der Heijden, Michiel S.
    Balar, Arjun V.
    Necchi, Andrea
    Dawson, Nancy
    O'Donnell, Peter H.
    Balmanoukian, Ani
    Loriot, Yohann
    Srinivas, Sandy
    Retz, Margitta M.
    Grivas, Petros
    Joseph, Richard W.
    Galsky, Matthew D.
    Fleming, Mark T.
    Petrylak, Daniel P.
    Perez-Gracia, Jose Luis
    Burris, Howard A.
    Castellano, Daniel
    Canil, Christina
    Bellmunt, Joaquim
    Bajorin, Dean
    Nickles, Dorothee
    Bourgon, Richard
    Frampton, Garrett M.
    Cui, Na
    Mariathasan, Sanjeev
    Abidoye, Oyewale
    Fine, Gregg D.
    Dreicer, Robert
    LANCET, 2016, 387 (10031): : 1909 - 1920
  • [5] Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)
    Holmsten, Karin
    Jensen, Niels Viggo
    Mouritsen, Lene Sonne
    Jonsson, Erika
    Mellnert, Camilla
    Agerbaek, Mads
    Nilsson, Cecilia
    Moe, Mette
    Carus, Andreas
    Ofverholm, Elisabeth
    Lahdenpera, Outi
    Brandberg, Yvonne
    Johansson, Hemming
    Hellstrom, Mats
    von der Maase, Hans
    Pappot, Helle
    Ullen, Anders
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 173 - 182
  • [6] Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial
    Oria, G. A. De Velasco
    Garcia-Carbonero, I.
    Esteban-Gonzalez, E.
    Pinto, A.
    Lorente, D.
    De Liano, A. Gomez
    Ortega, E. Martinez
    Colomo, L. Jimenez
    Puente, J.
    Gonzalez, I.
    Fernandez, O.
    Anguera, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1333 - S1333
  • [7] Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2016, 196 (06): : 1637 - 1638
  • [8] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [9] SIMULATING THE IMPACT OF FIRST-LINE TREATMENT CHOICE ON SURVIVAL AMONG PATIENTS WITH LOCALLY ADVANCED/METASTATIC UROTHELIAL CARCINOMA CONSIDERED CISPLATIN INELIGIBLE
    Galsky, M. D.
    Sonpavde, G. P.
    Bloudek, B.
    Farrar, M.
    Hepp, Z.
    Timmons, J.
    Dillon, R.
    Powles, T.
    VALUE IN HEALTH, 2023, 26 (06) : S18 - S18
  • [10] Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
    Vuky, Jacqueline
    Balar, Arjun Vasant
    Castellano, Daniel E.
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Hahn, Noah M.
    De Wit, Ronald
    Savage, Mary
    Pang, Lei
    Frenkl, Tara L.
    Keefe, Stephen Michael
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345